title: [The efficacy of human NGF dipeptide mimetic on the streptozotocin-induced model of diabetes in rats].
abstract: The effect of a new dimeric dipeptide mimetic GK-2 of the loop-4 human NGF (hexamethylendiamide-bis-N-monosuccinyl-glycil-L-lysine) was investigated for the first time on the dynamics of hyperglycemia and body weight loss caused in Wistar rats by streptozotocin (45 mg/kg i.p.) Prophylactic (2 weeks before streptozotocin) daily administration combined with therapeutic (4 weeks after STZ) administration of GK-2 (0.1 mg/kg i.p.) was shown to attenuate significantly the degree of hyperglycemia and to reverse the streptozotocin-induced weight loss.
authors.forename: I V
authors.initials: IV
authors.lastname: Ozerova
authors.forename: P Iu
authors.initials: PIu
authors.lastname: Povarnina
authors.forename: R U
authors.initials: RU
authors.lastname: Ostrovskaia
authors.forename: T A
authors.initials: TA
authors.lastname: Gudasheva
authors.forename: T A
authors.initials: TA
authors.lastname: Voronina
authors.forename: S B
authors.initials: SB
authors.lastname: Seredin
mesh_terms: D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000503:physiopathology; D004151:Dipeptides / Q000494:pharmacology*; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D020932:Nerve Growth Factor / Q000494:pharmacology*; D057786:Peptidomimetics / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D004151:Dipeptides; D057786:Peptidomimetics; C572946:bis(N-succinyl-glutamyllysin)hexamethylenediamine; D020932:Nerve Growth Factor